Tags

Type your tag names separated by a space and hit enter

Fucoidan protects against dopaminergic neuron death in vivo and in vitro.
Eur J Pharmacol. 2009 Sep 01; 617(1-3):33-40.EJ

Abstract

Parkinson's disease is a neurodegenerative disorder of uncertain pathogenesis characterized by a loss of dopaminergic neurons in substantia nigra pars compacta, and can be modeled by the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Oxidative stress may contribute to MPTP- and Parkinson's disease-related neurodegeneration. Fucoidan is a sulfated polysaccharide extracted from brown seaweeds which possesses a wide variety of biological activities including potent antioxidative effects. Here we investigated the effect of fucoidan treatment on locomoter activities of animals, striatal dopamine and its metabolites and survival of nigral dopaminergic neurons in MPTP-induced animal model of Parkinsonism in C57/BL mice in vivo and on the neuronal damage induced by 1-methyl-4-phenylpyridinium (MPP(+)) in vitro, and to study the possible mechanisms. When administered prior to MPTP, fucoidan reduced behavioral deficits, increased striatal dopamine and its metabolites levels, reduced cell death, and led to a marked increase in tyrosine hydroxylase expression relative to mice treated with MPTP alone. Furthermore, we found that fucoidan inhibited MPTP-induced lipid peroxidation and reduction of antioxidant enzyme activity. In addition, pre-treatment with fucoidan significantly protected against MPP(+)-induced damage in MN9D cells. Taken together, these findings suggest that fucoidan has protective effect in MPTP-induced neurotoxicity in this model of Parkinson's disease via its antioxidative activity.

Authors+Show Affiliations

Key Laboratory of Neurodegenerative Diseases of the Ministry of Education, Capital Medical University, Beijing, PR China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19545563

Citation

Luo, Dingzhen, et al. "Fucoidan Protects Against Dopaminergic Neuron Death in Vivo and in Vitro." European Journal of Pharmacology, vol. 617, no. 1-3, 2009, pp. 33-40.
Luo D, Zhang Q, Wang H, et al. Fucoidan protects against dopaminergic neuron death in vivo and in vitro. Eur J Pharmacol. 2009;617(1-3):33-40.
Luo, D., Zhang, Q., Wang, H., Cui, Y., Sun, Z., Yang, J., Zheng, Y., Jia, J., Yu, F., Wang, X., & Wang, X. (2009). Fucoidan protects against dopaminergic neuron death in vivo and in vitro. European Journal of Pharmacology, 617(1-3), 33-40. https://doi.org/10.1016/j.ejphar.2009.06.015
Luo D, et al. Fucoidan Protects Against Dopaminergic Neuron Death in Vivo and in Vitro. Eur J Pharmacol. 2009 Sep 1;617(1-3):33-40. PubMed PMID: 19545563.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fucoidan protects against dopaminergic neuron death in vivo and in vitro. AU - Luo,Dingzhen, AU - Zhang,Quanbin, AU - Wang,Haomin, AU - Cui,Yanqiu, AU - Sun,Zuoli, AU - Yang,Jian, AU - Zheng,Yan, AU - Jia,Jun, AU - Yu,Fen, AU - Wang,Xuan, AU - Wang,Xiaomin, Y1 - 2009/06/21/ PY - 2008/11/30/received PY - 2009/05/22/revised PY - 2009/06/03/accepted PY - 2009/6/24/entrez PY - 2009/6/24/pubmed PY - 2009/12/16/medline SP - 33 EP - 40 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 617 IS - 1-3 N2 - Parkinson's disease is a neurodegenerative disorder of uncertain pathogenesis characterized by a loss of dopaminergic neurons in substantia nigra pars compacta, and can be modeled by the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Oxidative stress may contribute to MPTP- and Parkinson's disease-related neurodegeneration. Fucoidan is a sulfated polysaccharide extracted from brown seaweeds which possesses a wide variety of biological activities including potent antioxidative effects. Here we investigated the effect of fucoidan treatment on locomoter activities of animals, striatal dopamine and its metabolites and survival of nigral dopaminergic neurons in MPTP-induced animal model of Parkinsonism in C57/BL mice in vivo and on the neuronal damage induced by 1-methyl-4-phenylpyridinium (MPP(+)) in vitro, and to study the possible mechanisms. When administered prior to MPTP, fucoidan reduced behavioral deficits, increased striatal dopamine and its metabolites levels, reduced cell death, and led to a marked increase in tyrosine hydroxylase expression relative to mice treated with MPTP alone. Furthermore, we found that fucoidan inhibited MPTP-induced lipid peroxidation and reduction of antioxidant enzyme activity. In addition, pre-treatment with fucoidan significantly protected against MPP(+)-induced damage in MN9D cells. Taken together, these findings suggest that fucoidan has protective effect in MPTP-induced neurotoxicity in this model of Parkinson's disease via its antioxidative activity. SN - 1879-0712 UR - https://www.unboundmedicine.com/medline/citation/19545563/Fucoidan_protects_against_dopaminergic_neuron_death_in_vivo_and_in_vitro_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(09)00514-7 DB - PRIME DP - Unbound Medicine ER -